throbber
{>\ BrightFocus"
`
`Foundation
`Cure in Mind. Cure in Sight.
`
`Macular
`Degeneration
`Research
`
`Age-Related Macular Degeneration: Facts
`& Figures
`
`Fact Sheet
`
`Published o n: July 13, 2021
`
`Adva nced age-related macular degeneration a leading cause of irreversible
`blindness and visual impa irment in the w o rld. As many as 11 millio n people in
`the United States have some form of age-related macular degeneration. Lea rn
`the facts about macular degeneration.
`
`Quick Facts about Macular Degeneration
`
`Macular degeneration can be very serious.
`
`https://www.brightfocus.org/macular/article/age-related-macular-facts-figures
`
`Novartis Exhibit 2261.001
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`Macular degeneration is a leading cause of vision loss in Americans 60
`years of age and older.
`
`Advanced age-related macular degeneration is a leading cause of
`irreversible blindness and visual impairment in the world.
`
`Age-related macular degeneration is an irreversible destruction of the
`macula, which leads to loss of the sharp, fine-detail, "straight ahead" vision
`required for activities like reading, driving, recognizing faces, and seeing
`the world in color.
`
`Macular degeneration is widespread.
`
`As many as 11 million people in the United States have some form of age(cid:173)
`related macular degeneration. This number is expected to double to nearly
`22 million by 2050.
`
`The number of people living with macular degeneration is expected to
`reach 196 million worldwide by 2020 and increase to 288 million by 2040.
`
`Age is a prominent risk factor for age-related macular degeneration. The
`risk of getting advanced age-related macular degeneration increases from
`2% for those ages 50-59, to nearly 30% for those over the age of 75.
`
`Macular degeneration is expensive, and will only become more
`expensive as the population aged 65 and older increases.
`
`Estimates of the global cost of visual impairment due to age-related
`macular degeneration is $343 billion, including $255 billion in direct health
`care costs.
`
`Estimates of the direct health care costs of visual impairment due to age(cid:173)
`related macular degeneration in the US, Canada, and Cuba (WHO
`subregion AMR-A), collectively, is approximately US$98 billion.
`
`The global cost of vision loss due to all causes is estimated to be nearly $3
`trillion dollars for the 733 million people living with low vision and
`blindness worldwide. In North America alone, the direct cost for vision loss
`
`
`https://www.brightfocus.org/macular/article/age-related-macular-facts-figures
`
`Novartis Exhibit 2261.002
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`due to all causes was $512.8 billion, and the indirect costs were $179
`billion.
`
`There are two forms of macular degeneration: dry and wet.
`
`The dry form of macular degeneration, in which the light sensitive cells of
`the macula slowly break down, is the most common type, accounting for
`90 percent of diagnosed cases.
`
`Wet macular degeneration accounts for approximately 10 percent of
`cases, but results in 90 percent of legal blindness. It is considered
`advanced macular degeneration (there is no early or intermediate stage of
`wet macular degeneration). Wet macular degeneration is always preceded
`by the dry form of the disease.
`
`It is possible for dry macular degeneration to advance and cause loss of
`vision without turning into the wet form of the disease; however, it is also
`possible for early-stage dry age-related macular degeneration to suddenly
`change into the wet form.
`
`An eye care professional can help diagnose macular
`degeneration and determine which form(s) of the disease you
`have.
`
`To help diagnose macular degeneration, an eye care professional will
`perform a dilated eye exam, fundoscopy, a visual acuity test, and fundus
`photography. If wet age-related macular degeneration is suspected,
`fluorescein angiography may be performed, in which dye is used to detect
`leaking blood vessels. The patient may also be asked to look at an Amsler
`grid.
`
`There is no treatment or cure for advanced dry macular
`degeneration. But a specific high-dose formula of antioxidant
`vitamins and zinc may delay or prevent intermediate macular
`degeneration from progressing to the advanced stage.
`
`https://www.brightfocus.org/macular/article/age-related-macular-facts-figures
`
`Novartis Exhibit 2261.003
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`Approved drugs and medications:
`
`Beovu® (brolucizumab)
`
`Eylea™ (aflibercept),
`
`Lucentis® (ranibizumab)
`
`Macugen® (pegaptanib)
`
`Photodynamic therapy:
`
`Treatment that can help control the abnormal blood vessel growth and
`bleeding in the macula for those with wet macular degeneration)
`
`Physicians have also used:
`
`Avastin™ (bevacizumab injection), a cancer therapy manufactured by
`the company that makes Lucentis, as an "off-label" treatment for wet
`macular degeneration.
`
`Vision rehabilitation and low vision aids:
`
`Help improve the quality of life for those who are visually impaired
`
`A healthy lifestyle may help reduce the risk of developing
`macular degeneration.
`
`The following lifestyle changes are recommended:
`
`Don't smoke
`
`Exercise regularly
`
`Keep blood pressure in a normal range and control other medical
`conditions
`
`Maintain a healthy weight
`
`
`https://www.brightfocus.org/macular/article/age-related-macular-facts-figures
`
`Novartis Exhibit 2261.004
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`Eat a diet high in fruits, vegetables and fish, and in low foods that
`rapidly raise blood sugar
`
`Protect eyes from overexposure to sunlight with sunglasses and hats
`
`Promising Research
`
`Ongoing research is exploring environmental, genetic, and dietary factors that
`may contribute to macular degeneration. New treatment strategies are also
`being investigated, including :
`
`retinal cell transplants
`
`drugs to prevent or slow disease progress
`
`radiation therapy
`
`gene therapies
`
`a computer chip implanted in the retina that may help simulate vision
`
`agents that will prevent new blood vessel growth under the macula.
`
`Help find a cure
`
`Donate to help end Macular Degeneration Disease
`
`I would like to donate
`
`G 0 G
`
`( szso ) ( s1000 )
`
`OthPr
`(
`https://www.brightfocus.org/macular/article/age-related-macular-facts-figures
`
`)
`
`Novartis Exhibit 2261.005
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`\.. __ )
`
`Donate Now
`
`Stay in touch
`
`Receive Macular Degeneration research updates and inspiring
`stories
`
`First Name
`
`'---
`
`Last Name
`
`Your Email Address
`
`Submit
`
`https://www.brightfocus.org/macular/article/age-related-macular-facts-figures
`
`Novartis Exhibit 2261.006
`Regeneron v. Novartis, IPR2021-00816
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket